Comparative Safety of Advanced Therapies for Crohn Disease

What is the comparative safety of different advanced therapies in patients with Crohn disease (CD)?In this comparative effectiveness research study of 12 245 patients with CD, treated with tumor necrosis factor-α antagonists, vedolizumab, ustekinumab, risankizumab, or upadacitinib and followed up over a mean 27 months, no clinically meaningful differences in the risk of key safety events, including serious infections, venous thromboembolism, and major adverse cardiovascular events, were found. The incidence of venous thromboembolism and major adverse cardiovascular events was low across all therapies.The findings of this study suggest that the safety of different advanced therapies in patients with CD was comparable and should not be the primary driver of treatment positioning in most instances.

Corresponding Author: Siddharth Singh, MD, Division of Gastroenterology and Hepatology, Department of Medicine, Mayo Clinic in Arizona, Scottsdale, AZ 85259 (singh.siddharth@mayo.edu).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.